newsfilter
← Latest News
ACCESS Newswire·

Xenetic Biosciences Reports First Quarter 2026 Financial Results and Highlights Continued Advancement of DNase Oncology Platform

Advancements across investigator-initiated studies, translational research and manufacturing activities supporting future clinical developmentStrengthened financial profile with continued royalty revenue growthEnded